La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Kyowa Kirin Gestione

Gestione criteri di controllo 3/4

Kyowa Kirin's Il CEO è Masashi Miyamoto, nominato in Mar2018, e ha un mandato di 6.42 anni. la retribuzione annua totale è ¥ 157.00M, composta da 52.9% di stipendio e 47.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.018% delle azioni della società, per un valore di ¥ 298.03M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3 anni e 2.9 anni.

Informazioni chiave

Masashi Miyamoto

Amministratore delegato

JP¥157.0m

Compenso totale

Percentuale dello stipendio del CEO	52.9%
Mandato del CEO	6.4yrs
Proprietà del CEO	0.02%
Durata media del management	3yrs
Durata media del Consiglio di amministrazione	2.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Kyowa Kirin Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 03

Earnings Miss: Kyowa Kirin Co., Ltd. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

May 09

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Apr 25

Kyowa Kirin's (TSE:4151) Dividend Will Be ¥29.00

Apr 11

Here's Why We Think Kyowa Kirin (TSE:4151) Is Well Worth Watching

Mar 19

Kyowa Kirin Co., Ltd.'s (TSE:4151) 26% Price Boost Is Out Of Tune With Earnings

Feb 27

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Masashi Miyamoto rispetto agli utili di Kyowa Kirin?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	JP¥97b
Mar 31 2024	n/a	n/a	JP¥83b
Dec 31 2023	JP¥157m	JP¥83m	JP¥81b
Sep 30 2023	n/a	n/a	JP¥58b
Jun 30 2023	n/a	n/a	JP¥40b
Mar 31 2023	n/a	n/a	JP¥50b
Dec 31 2022	JP¥182m	JP¥83m	JP¥54b

Compensazione vs Mercato: La retribuzione totale di Masashi ($USD 1.07M ) è inferiore alla media delle aziende di dimensioni simili nel mercato JP ($USD 1.64M ).

Compensazione vs guadagni: La retribuzione di Masashi è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Masashi Miyamoto (65 yo)

6.4yrs

Mandato

JP¥157,000,000

Compensazione

Mr. Masashi Miyamoto Ph D., serves as Representative Director at Kyowa Kirin Co., Ltd. He serves as President of Kyowa Hakko Kirin Co., Ltd since March 2018, served as a Chief Operating Officer since March...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Masashi Miyamoto	President	6.4yrs	JP¥157.00m	0.018% ¥ 298.0m
Motohiko Kawaguchi	CFO & Managing Executive Officer	no data	Nessun dato	Nessun dato
Yutaka Osawa	CCO, Executive VP & Representative Director	2.6yrs	JP¥105.00m	0.013% ¥ 208.4m
Kazuki Nemoto	Head of Global Legal	1.3yrs	Nessun dato	Nessun dato
Hiroki Nakamura	Global Corporate Communications Head	no data	Nessun dato	Nessun dato
Hiroshi Sonekawa	Managing Executive Officer	3.4yrs	Nessun dato	Nessun dato
Takeyoshi Yamashita	Chief Medical Officer	3.6yrs	Nessun dato	0.0052% ¥ 84.4m
Yasuo Fujii	Chief Strategy Officer	6.6yrs	Nessun dato	Nessun dato
Jean-David Rafizadeh-Kabe	Head of Global Operational Transformation	2.6yrs	Nessun dato	Nessun dato
Yoshifumi Torii	Executive Officer & Head of Global Research	no data	Nessun dato	Nessun dato
Hiroki Takamatsu	VP, Head of Quality Assurance Division & Executive Officer	no data	Nessun dato	Nessun dato
Tomohiro Sudo	Executive Officer & Head of Global Product strategy	2.6yrs	Nessun dato	Nessun dato

3.0yrs

Durata media

65yo

Età media

Gestione esperta: Il team dirigenziale di 4151 è considerato esperto (durata media dell'incarico 3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Masashi Miyamoto	President	13.3yrs	JP¥157.00m	0.018% ¥ 298.0m
Yutaka Osawa	CCO, Executive VP & Representative Director	6.4yrs	JP¥105.00m	0.013% ¥ 208.4m
Takeyoshi Yamashita	Chief Medical Officer	1.4yrs	Nessun dato	0.0052% ¥ 84.4m
Yoshihisa Q. Suzuki	Independent Outside Director	2.4yrs	Nessun dato	0.00025% ¥ 4.1m
Hiroshi Komatsu	Full-time Audit & Supervisory Board Member	6.4yrs	Nessun dato	0.00085% ¥ 13.8m
Akira Morita	Outside Independent Chairman	5.4yrs	Nessun dato	0.00066% ¥ 10.7m
Yuko Haga	Independent Outside Director	5.4yrs	Nessun dato	0.00085% ¥ 13.8m
Mayumi Tamura	Outside Audit & Supervisory Board Member	2.4yrs	Nessun dato	0.00011% ¥ 1.8m
Takashi Oyamada	Independent Outside Director	3.4yrs	Nessun dato	0.00059% ¥ 9.6m
Shinjiro Akieda	Director	less than a year	Nessun dato	Nessun dato
Rumiko Nakata	Independent Outside Director	1.4yrs	Nessun dato	0.000040% ¥ 650.4k
Toru Ishikura	Audit & Supervisory Board Member	1.4yrs	Nessun dato	Nessun dato

2.9yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 4151 non è considerato esperto (durata media del mandato 2.9 anni), il che suggerisce un nuovo consiglio.

Kyowa Kirin Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 22, 2024

High number of new directors

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 24, 2023

High number of new directors

High number of new directors

High number of new directors

Recent updates

Kyowa Kirin Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Kyowa Kirin Co., Ltd. Updates Earnings Guidance for He Fiscal Year 2024

Here's Why Kyowa Kirin (TSE:4151) Has Caught The Eye Of Investors

Kyowa Kirin Co., Ltd.'s (TSE:4151) Share Price Could Signal Some Risk

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Are Investors Undervaluing Kyowa Kirin Co., Ltd. (TSE:4151) By 35%?

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2024 Results on Feb 06, 2025

Earnings Miss: Kyowa Kirin Co., Ltd. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

First quarter 2024 earnings: EPS misses analyst expectations

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Kyowa Kirin's (TSE:4151) Dividend Will Be ¥29.00

Final dividend of JP¥29.00 announced

Here's Why We Think Kyowa Kirin (TSE:4151) Is Well Worth Watching

Kyowa Kirin Co., Ltd. to Present Phase 2B Post-Hoc Analysis and Symposium At the American Academy of Dermatology Annual Meeting 2024

Kyowa Kirin Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Kyowa Kirin Co., Ltd.'s (TSE:4151) 26% Price Boost Is Out Of Tune With Earnings

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

Kyowa Kirin Co., Ltd. Declares Dividend for the Fiscal Year Ended December 31, 2023, Payable on March 25, 2024; Provides Dividend Guidance for the Second Quarter of 2024

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 22, 2024

Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2023 Results on Feb 07, 2024

Upcoming dividend of JP¥27.00 per share at 2.3% yield

Now 20% undervalued after recent price drop

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Kyowa Kirin Co., Ltd. (TSE:4151) entered into a Transaction Agreement to acquire Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others for approximately $470 million.

Kyowa Kirin Co., Ltd. to Report Q3, 2023 Results on Nov 01, 2023

New minor risk - Earnings quality

New minor risk - Profit margin trend

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

Upcoming dividend of JP¥27.00 per share at 2.0% yield

Kyowa Kirin Co., Ltd. to Report Q1, 2024 Results on Aug 03, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Year Ending December 31, 2023

High number of new directors

Full year 2022 earnings: EPS misses analyst expectations

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 24, 2023

Kyowa Kirin Co., Ltd. Declares Dividend for the Fiscal Year Ended December 31, 2022, Payable on March 27, 2023; Provides Dividend Guidance for the Second Quarter of 2023

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2022 Results on Feb 07, 2023

Upcoming dividend of JP¥24.00 per share

Consensus forecasts updated

Kyowa Kirin Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended December 31, 2022

Kyowa Kirin Co., Ltd. and MEI Pharma, Inc. Announce Topline Data from Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-Cell Non-Hodgkin’s Lymphoma in Japan

High number of new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending December 31, 2022

Kyowa Kirin Co., Ltd. Receives European Commission Approval for Use of CRYSVITA(R) (burosumab) for the Treatment of Tumour-Induced Osteomalacia

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Kyowa Kirin Co., Ltd. Announces Second Quarter End Dividend for the Fiscal Year Ending December 31, 2022, Payable from September 1, 2022; Provided Year End Dividend Guidance for the Fiscal Year Ending December 31, 2022

MEI Pharma and Kyowa Kirin Announce Publication in the Lancet Oncology of Data from Phase 1B Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-Cell Malignancy

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)

Upcoming dividend of JP¥24.00 per share

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year Ending December 31, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new directors

High number of new directors

Now 20% undervalued after recent price drop

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 25, 2022

Full year 2021 earnings: EPS exceeds analyst expectations

Upcoming dividend of JP¥23.00 per share

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce Data from Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma